Orca Bio

Executive Summary

Orca Bio is a late-stage biotechnology company pioneering high-precision allogeneic T-cell immunotherapies for cancer and autoimmune diseases. Founded in 2016 and headquartered in Menlo Park, California, the company aims to deliver the promise of cell therapy without compromise, initially targeting high-risk blood cancers. Orca Bio's platform enables the precise selection of T-cell subsets to create a more targeted and safer therapy, potentially reducing graft-versus-host disease while preserving anti-cancer activity. The company is well-positioned to address significant unmet needs in hematopoietic stem cell transplantation and autoimmune disorders, with a robust pipeline of product candidates. As a private entity, Orca Bio has attracted substantial venture capital backing and is advancing toward pivotal clinical trials. The next 12-18 months are critical as the company prepares for potential regulatory interactions and data readouts that could validate its platform and drive significant value inflection.

Upcoming Catalysts (preview)

• Q2 2027Phase 2 clinical data readout for Orca-T in high-risk blood cancers70% success
• Q4 2026Initiation of pivotal trial for Orca-T in autoimmune diseases60% success
• Q3 2026Potential partnership or licensing deal with a major pharmaceutical company50% success